These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

377 related articles for article (PubMed ID: 22807503)

  • 21. Phosphorus and other aspects of CKD-MBD in the conservative management of chronic kidney disease.
    Shah A
    Panminerva Med; 2017 Jun; 59(2):124-132. PubMed ID: 28290186
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Calcium regulation and bone mineral metabolism in elderly patients with chronic kidney disease.
    Tejwani V; Qian Q
    Nutrients; 2013 May; 5(6):1913-36. PubMed ID: 23760058
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Management of phosphorus load in CKD patients.
    Taketani Y; Koiwa F; Yokoyama K
    Clin Exp Nephrol; 2017 Mar; 21(Suppl 1):27-36. PubMed ID: 27896453
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The role of fibroblast growth factor 23 in chronic kidney disease-mineral and bone disorder.
    Diniz H; Frazão JM
    Nefrologia; 2013 Nov; 33(6):835-44. PubMed ID: 24158124
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Treatment of CKD-MBD targeting the parathyroid gland].
    Isozaki Y; Komaba H
    Clin Calcium; 2016 Jun; 26(6):895-903. PubMed ID: 27230846
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Parathyroid and bone. Mineral and bone disorder and parathyroid function in chronic kidney disease].
    Yano S
    Clin Calcium; 2007 Dec; 17(12):1870-8. PubMed ID: 18057663
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The future of phosphate binders: a perspective on novel therapeutics.
    Cernaro V; Santoro D; Lucisano S; Nicocia G; Lacquaniti A; Buemi M
    Expert Opin Investig Drugs; 2014 Nov; 23(11):1459-63. PubMed ID: 25243756
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Paricalcitol and cardiorenal outcome: from the IMPACT study to clinical practice.
    Bellasi A; Galassi A; Salvi P; Cozzolino M
    Blood Purif; 2013; 36(1):12-6. PubMed ID: 23736115
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Kidney and bone update : the 5-year history and future of CKD-MBD. Bisphosphonates treatment for chronic kidney disease-mineral and bone disorder].
    Mori H; Okada Y; Tanaka Y; Hashimoto O
    Clin Calcium; 2012 Jul; 22(7):1034-42. PubMed ID: 22750936
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Recovery versus persistence of disordered mineral metabolism in kidney transplant recipients.
    Evenepoel P
    Semin Nephrol; 2013 Mar; 33(2):191-203. PubMed ID: 23465505
    [TBL] [Abstract][Full Text] [Related]  

  • 31. FGF-23 and osteoprotegerin are independently associated with myocardial damage in chronic kidney disease stages 3 and 4. Another link between chronic kidney disease-mineral bone disorder and the heart.
    Ford ML; Smith ER; Tomlinson LA; Chatterjee PK; Rajkumar C; Holt SG
    Nephrol Dial Transplant; 2012 Feb; 27(2):727-33. PubMed ID: 21750158
    [TBL] [Abstract][Full Text] [Related]  

  • 32. FGF-23: the rise of a novel cardiovascular risk marker in CKD.
    Heine GH; Seiler S; Fliser D
    Nephrol Dial Transplant; 2012 Aug; 27(8):3072-81. PubMed ID: 22851630
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Chronic kidney disease-mineral-bone disorder: a new paradigm.
    Moe SM; Drüeke T; Lameire N; Eknoyan G
    Adv Chronic Kidney Dis; 2007 Jan; 14(1):3-12. PubMed ID: 17200038
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [CKD-MBD (Chronic Kidney Disease-Mineral and Bone Disorder). KDIGO CKD-MBD Clinical Practice Guideline].
    Tsukamoto Y
    Clin Calcium; 2010 Jul; 20(7):1021-7. PubMed ID: 20585180
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Women and CKD-mineral and bone disorder.
    Ho LT; Sprague SM
    Adv Chronic Kidney Dis; 2013 Sep; 20(5):423-6. PubMed ID: 23978548
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Chronic kidney disease (CKD) and bone. CKD-MBD managements and view in the future].
    Watanabe M; Suzuki H; Akizawa T
    Clin Calcium; 2009 Apr; 19(4):559-65. PubMed ID: 19329836
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Magnesium disorder and its clinical significance in chronic kidney disease].
    Okuno S
    Clin Calcium; 2012 Aug; 22(8):1243-9. PubMed ID: 22846361
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Effects of SERMs on bone health. The potential of SERM in the care of chronic kidney disease-mineral bone and disorders].
    Hamano T
    Clin Calcium; 2010 Mar; 20(3):373-9. PubMed ID: 20190367
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Revisiting KDIGO clinical practice guideline on chronic kidney disease-mineral and bone disorder: a commentary from a Kidney Disease: Improving Global Outcomes controversies conference.
    Ketteler M; Elder GJ; Evenepoel P; Ix JH; Jamal SA; Lafage-Proust MH; Shroff R; Thadhani RI; Tonelli MA; Kasiske BL; Wheeler DC; Leonard MB
    Kidney Int; 2015 Mar; 87(3):502-28. PubMed ID: 25651364
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [CKD-MBD (Chronic Kidney Disease-Mineral and Bone Disorder). Paradigm shift in CKD-MBD guideline].
    Yokoyama K
    Clin Calcium; 2010 Jul; 20(7):1012-20. PubMed ID: 20585179
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.